Gastroenteropancreatic (GEP) neuroendocrine tumors(NET) are rare tumors with a low incidence of at least 3–5/100,000 but a considerably higher prevalence of 35/100,000. The majority of patients at the time of diagnosis are found to have an advanced stage of the disease. Bone metastasis is not an infrequent complication in most neoplasms and has been found in 70–85% of cancer patients at autopsy. GEP-NET bone metastases frequently remain undetected. They are often accompanied by widespread extraosseous metastases and are found to occur predominantly in patients with liver metastases. It is thought that lung metastases occur with a similar frequency to bone metastases
ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.
FALCONI, Massimo;
2010-01-01
Abstract
Gastroenteropancreatic (GEP) neuroendocrine tumors(NET) are rare tumors with a low incidence of at least 3–5/100,000 but a considerably higher prevalence of 35/100,000. The majority of patients at the time of diagnosis are found to have an advanced stage of the disease. Bone metastasis is not an infrequent complication in most neoplasms and has been found in 70–85% of cancer patients at autopsy. GEP-NET bone metastases frequently remain undetected. They are often accompanied by widespread extraosseous metastases and are found to occur predominantly in patients with liver metastases. It is thought that lung metastases occur with a similar frequency to bone metastases
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
